Vedanta Biosciences, Inc.

This study is testing whether a 14-day course of an investigational oral drug called VE303 can prevent a C. difficile infection from coming back after standard antibiotic treatment. It will enroll 852 people who have just been treated for a C. diff infection and are at high risk …